Fragile X drug developer Fulcrum to use Horizon's CRISPR to find gene targets
Fulcrum Therapeutics will use a CRISPR gene editing-based platform to identify genetic targets under a deal with Horizon Discovery Group.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs